Readily available biomarkers predict poor survival in metastatic pancreatic cancer
| العنوان: | Readily available biomarkers predict poor survival in metastatic pancreatic cancer |
|---|---|
| المؤلفون: | Strijker, M., Veldhuisen, E. van, Geest, L.G. van der, Busch, O.R., Bijlsma, M.F., Mohammad, N.H., Homs, M.Y., Hooft, J.E. van, Verheij, J., Vos-Geelen, J. de, Wilmink, J.W., Steyerberg, W.E.W., Besselink, M.G., Laarhoven, H.W. van, Dutch Pancreatic Canc Grp |
| المساهمون: | Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Medical Oncology, Graduate School, CCA - Cancer Treatment and Quality of Life, Amsterdam Gastroenterology Endocrinology Metabolism, Surgery, Center of Experimental and Molecular Medicine, Radiotherapy, CCA - Imaging and biomarkers, Gastroenterology and Hepatology, Pathology, Oncology |
| المصدر: | Biomarkers, 26(4), 325-334. Routledge/Taylor & Francis Group Biomarkers, 26(4), 325-334. TAYLOR & FRANCIS LTD Biomarkers, 26(4), 325-334. Informa Healthcare Biomarkers |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Oncology, Male, medicine.medical_specialty, CA-19-9 Antigen, Health, Toxicology and Mutagenesis, medicine.medical_treatment, GPS, Clinical Biochemistry, Kaplan-Meier Estimate, 030204 cardiovascular system & hematology, Logistic regression, Biochemistry, Sensitivity and Specificity, 03 medical and health sciences, 0302 clinical medicine, SDG 3 - Good Health and Well-being, Predictive Value of Tests, Internal medicine, Pancreatic cancer, medicine, Biomarkers, Tumor, Humans, Registries, Neoplasm Metastasis, Serum Albumin, Aged, Netherlands, Retrospective Studies, Chemotherapy, Performance status, L-Lactate Dehydrogenase, business.industry, Middle Aged, medicine.disease, Cancer registry, population-based, Clinical trial, Pancreatic Neoplasms, C-Reactive Protein, Logistic Models, 030220 oncology & carcinogenesis, Cohort, Multivariate Analysis, readily available biomarkers, Biomarker (medicine), Female, prognosis, business |
| الوصف: | BackgroundIdentification of metastatic pancreatic cancer (mPC) patients with the worst prognosis could help to tailor therapy. We evaluated readily available biomarkers for the prediction of 90-day mortality in a nationwide cohort of mPC patients.MethodsPatients with synchronous mPC were included from the Netherlands Cancer Registry (2015-2017). Baseline CA19-9, albumin, CRP, LDH, CRP/albumin ratio, and (modified) Glasgow Prognostic Score ((m)GPS composed of albumin and CRP) were evaluated. Multivariable logistic regression analyses were performed to identify predictors of 90-day mortality. Prognostic value per predictor was quantified by Nagelkerke's partial R-2.ResultsOverall, 4248 patients were included. Median overall survival was 2.2 months and 90-day mortality was 59.4% (n = 1629). All biomarkers predicted 90-day mortality in univariable analysis, and remained statistically significant after adjustment for clinically relevant factors and all other biomarkers (all p < 0.001). The prognostic value of the biomarkers combined was similar to WHO performance status. Patients who received chemotherapy had better outcomes than those who did not, regardless of biomarker levels.ConclusionsIn mPC patients, albumin, CA19-9, CRP, LDH, CRP/albumin ratio, and (m)GPS are prognostic for poor survival. Biomarkers did not predict response to chemotherapy. These readily available biomarkers can be used to better inform patients and to stratify in clinical trials. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1354-750X |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d16dd3ba3c2689d4fe6a80f266e8fd8Test https://doi.org/10.1080/1354750x.2021.1893814Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....2d16dd3ba3c2689d4fe6a80f266e8fd8 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 1354750X |
|---|